192 related articles for article (PubMed ID: 36028328)
1. Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
Tangen GG; Nilsson MH; Stomrud E; Palmqvist S; Hansson O
Neurology; 2022 Nov; 99(19):e2081-e2091. PubMed ID: 36028328
[TBL] [Abstract][Full Text] [Related]
2. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.
Mazzeo S; Ingannato A; Giacomucci G; Manganelli A; Moschini V; Balestrini J; Cavaliere A; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Bagnoli S; Padiglioni S; Sorbi S; Nacmias B; Bessi V
Eur J Neurol; 2024 Jan; 31(1):e16089. PubMed ID: 37797300
[TBL] [Abstract][Full Text] [Related]
3. Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
Planche V; Bouteloup V; Pellegrin I; Mangin JF; Dubois B; Ousset PJ; Pasquier F; Blanc F; Paquet C; Hanon O; Bennys K; Ceccaldi M; Annweiler C; Krolak-Salmon P; Godefroy O; Wallon D; Sauvee M; Boutoleau-Bretonnière C; Bourdel-Marchasson I; Jalenques I; Chene G; Dufouil C;
Neurology; 2023 Jan; 100(5):e473-e484. PubMed ID: 36261295
[TBL] [Abstract][Full Text] [Related]
4. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
[TBL] [Abstract][Full Text] [Related]
5. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
[TBL] [Abstract][Full Text] [Related]
6. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
7. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
8. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
[TBL] [Abstract][Full Text] [Related]
9. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis.
Rostamzadeh A; Bohr L; Wagner M; Baethge C; Jessen F
Neurology; 2022 Oct; 99(17):e1866-e1874. PubMed ID: 36028322
[TBL] [Abstract][Full Text] [Related]
10. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
[TBL] [Abstract][Full Text] [Related]
12. The free plasma amyloid Aβ
Schraen-Maschke S; Duhamel A; Vidal JS; Ramdane N; Vaudran L; Dussart C; Buée L; Sablonnière B; Delaby C; Allinquant B; Gabelle A; Bombois S; Lehmann S; Hanon O;
Neurobiol Dis; 2024 Apr; 193():106459. PubMed ID: 38423192
[TBL] [Abstract][Full Text] [Related]
13. Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease.
Tangen GG; Engedal K; Bergland A; Moger TA; Hansson O; Mengshoel AM
Int Psychogeriatr; 2015 Aug; 27(8):1401-9. PubMed ID: 25644091
[TBL] [Abstract][Full Text] [Related]
14. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tau deposition using
Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
[TBL] [Abstract][Full Text] [Related]
16. Association of CSF Aβ
Cullen N; Janelidze S; Palmqvist S; Stomrud E; Mattsson-Carlgren N; Hansson O;
Neurology; 2022 Mar; 98(9):e958-e967. PubMed ID: 34937781
[TBL] [Abstract][Full Text] [Related]
17. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults.
Levine TF; Dessenberger SJ; Allison SL; Head D;
J Int Neuropsychol Soc; 2024 May; 30(4):313-327. PubMed ID: 38014546
[TBL] [Abstract][Full Text] [Related]
19. Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
Prosser L; Macdougall A; Sudre CH; Manning EN; Malone IB; Walsh P; Goodkin O; Pemberton H; Barkhof F; Biessels GJ; Cash DM; Barnes J;
Neurology; 2023 Feb; 100(8):e834-e845. PubMed ID: 36357185
[TBL] [Abstract][Full Text] [Related]
20. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
